Jianhua Liao

Dr. Jianhua Liao


Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 November 2018 in PLOS ONE
Verified
Journal Article
Open access
PDF file
CMChunyan Meng
Chunyan Meng
XYXiaowei Yin
Xiaowei Yin
JLJingting Liu
Jingting Liu
KTKaifeng Tang
Kaifeng Tang
HTHongchao Tang
Hongchao Tang
JLJianhua Liao
Jianhua Liao
Tissue inhibitor of metalloproteinase-1 (TIMP-1) is a glycoprotein involved in cell survival and tumorigenesis. There have been some promising results regarding the diagnostic value of TIMP-1 for patients with colorectal cancer (CRC). The aim of the present study was to assess the diagnostic accuracy and clinical utility of serum TIMP-1 in CRC patients through meta-analysis. A systematic search of online databases was performed to collect eligible studies. The pooled sensitivity, specificity, diagnostic odds ratio (DOR), and summary receiver operator characteristic (SROC) curve were generated from accuracy data using the random-effects model. Fagan’s nomogram and the likelihood matrix were applied to estimate the clinical utility of TIMP-1. A total of 9 eligible studies with 1886 patients were included. Among the patients, 819 were pathologically diagnosed with CRC, whereas 1067 did not have adenomas or other cancers. The overall sensitivity, specificity, and DOR of TIMP-1 for the diagnosis of CRC were 0.65 (95% confidence interval (CI): 0.57–0.72), 0.87 (95% CI: 0.76–0.94), and 12.73 (95% CI 5.71–28.38), respectively. The area under the SROC was 0.77 (95% CI, 0.73–0.81), suggesting the potential diagnostic value of TIMP-1 in CRC patients. Among patients with a pretest CRC probability of 20%, posttest probabilities were 56% and 9% for positive and negative TIMP-1 results, respectively. TIMP-1 expression exhibits an upper moderate diagnostic value in CRC, and TIMP-1 assessment may be useful as a noninvasive screening tool for CRC in clinical practice.

11 April 2025 in BMC Cancer
Verified
Journal Article
Open access
PDF file
BWBo Wu
Bo Wu
JLJingting Liu
Jingting Liu
CSChaodan Shao
Chaodan Shao
DYDongli Yu
Dongli Yu
JLJianhua Liao
Jianhua Liao
Digestive system cancers remain a leading cause of cancer-related mortality globally, underscoring the need for reliable prognostic tools. The C-reactive protein-Albumin-Lymphocyte (CALLY) index, which reflects inflammation, nutrition, and immunity, has shown potential in predicting survival. However, comprehensive evaluations of its role in digestive system cancers are still limited. A meta-analysis of English-language studies from online databases was performed to assess the prognostic value of the CALLY index. Pooled hazard ratios (HRs) were calculated for overall survival (OS), disease-free survival (DFS), recurrence-free survival (RFS), and cancer-specific survival (CSS). A total of eighteen articles (19 studies, encompassing 7,951 patients) were included. A lower CALLY index was significantly associated with poorer outcomes across all survival endpoints. The pooled HR for OS was 1.973 (95% CI: 1.734–2.244), with HRs for DFS, RFS, and CSS being 2.093 (95% CI: 1.682–2.604), 1.462 (95% CI: 1.292–1.654), and 2.456 (95% CI: 1.887–3.221), respectively (all P < 0.001). Subgroup analyses for OS demonstrated consistent prognostic significance across various treatment strategies, cancer types, cutoff values, sample sizes, and regions. Notably, the CALLY index was a strong predictor of OS in surgical patients (HR = 2.014, 95% CI: 1.794–2.260, P < 0.001). Sensitivity analyses validated the robustness of these findings, with minimal publication bias (Egger’s test P = 0.053). The CALLY index serves as a cost-effective and reliable biomarker for predicting prognosis in digestive system cancers. Its utility as a pre-treatment risk stratification tool, which integrates key factors of inflammation, nutrition, and immunity, renders it valuable for guiding clinical decision-making.

27 September 2018 in Cell Death & Disease
Verified
Journal Article
Open access
PDF file
CLChangcan Li
Changcan Li
XLXisheng Liu
Xisheng Liu
YLYuan Liu
Yuan Liu
XLXueni Liu
Xueni Liu
RWRangrang Wang
Rangrang Wang
ZWZhaowen Wang
Zhaowen Wang
Little is known about the function of Keratin 80 (KRT80), an epithelial keratin, in cancer. This study investigated the role of KRT80 in the prognosis of colorectal carcinoma (CRC) and the underlying mechanisms involved in CRC migration and invasion. We analyzed the expression of KRT80 using The Cancer Genome Atlas and Oncomine databases. Higher expression of KRT80 was found to be significantly associated with multiple pathological parameters, lower disease-free survival, and overall survival in CRC patients. Also, KRT80 was an independent prognostic indicator for CRC. Furthermore, altered KRT80 expression impacted migration and invasion of CRC cells, as well as the expression of epithelial–mesenchymal transition (EMT)-related markers and cell morphology via the AKT pathway. Inhibiting the expression of AKT could reverse these phenomena. Liquid Chromatograph Mass Spectrometer/Mass Spectromete, Co-immunoprecipitation, and laser scanning confocal microscopy techniques showed that KRT80 could interact with protein kinase, DNA-activated, catalytic polypeptide (PRKDC). Suppressing PRKDC could inhibit the expression of AKT and EMT, as well as the migration and invasion of CRC cells. Taken together, these results demonstrated that KRT80 was an independent prognostic biomarker for CRC and promoted CRC migration and invasion by interacting with PRKDC via activation of the AKT pathway.

29 October 2022 in World Journal of Surgical Oncology
Verified
Journal Article
Open access
PDF file
DZDan Zhang
Dan Zhang
JLJingting Liu
Jingting Liu
MZMengxia Zheng
Mengxia Zheng
CMChunyan Meng
Chunyan Meng
JLJianhua Liao
Jianhua Liao
Background: It has been previously reported that CD155 is often over-expressed in a variety of cancer types. In fact, it is known to be involved in cancer development, and its role in cancer has been widely established. However, clinical and mechanistic studies involving CD155 yielded conflicting results. Thus, the present study aimed to evaluate overall prognostic value of CD155 in cancer patients, using a comprehensive analysis. Methods: Online databases were searched, data was collected, and clinical value of CD155 was evaluated by combining hazard ratios (HRs) or odds ratios (ORs). Results: The present study involved meta-analysis of 26 previous studies that involved 4325 cancer patients. These studies were obtained from 25 research articles. The results of the study revealed that increased CD155 expression was significantly associated with reduced OS in patients with cancer as compared to low CD155 expression (pooled HR = 1.772, 95% CI = 1.441–2.178, P < 0.001). Furthermore, subgroup analysis demonstrated that the level of CD155 expression was significantly associated with OS in patients with digestive system cancer (pooled HR = 1.570, 95% CI = 1.120–2.201, P = 0.009), hepatobiliary pancreatic cancer (pooled HR = 1.677, 95% CI = 1.037–2.712, P = 0.035), digestive tract cancer (pooled HR = 1.512, 95% CI = 1.016–2.250, P = 0.042), breast cancer (pooled HR = 2.137, 95% CI = 1.448–3.154, P < 0.001), lung cancer (pooled HR = 1.706, 95% CI = 1.193–2.440, P = 0.003), head and neck cancer (pooled HR = 1.470, 95% CI = 1.160–1.862, P = 0.001). Additionally, a significant correlation was observed between enhanced CD155 expression and advanced tumor stage (pooled OR = 1.697, 95% CI = 1.217–2.366, P = 0.002), LN metastasis (pooled OR = 1.953, 95% CI = 1.253–3.046, P = 0.003), and distant metastasis (pooled OR = 2.253, 95% CI = 1.235–4.110, P = 0.008). Conclusion: Altogether, the results of the present study revealed that CD155 acted as an independent marker of prognosis in cancer patients, and it could provide a new and strong direction for cancer treatment.

14 October 2025 in BMC Cancer
Verified
Journal Article
Open access
PDF file
CQCaihua Qian
Caihua Qian
JLJingting Liu
Jingting Liu
CMChunyan Meng
Chunyan Meng
JCJun Cheng
Jun Cheng
BWBo Wu
Bo Wu
JLJianhua Liao
Jianhua Liao
Digestive system cancers are a major global health burden, necessitating reliable and cost-effective prognostic biomarkers for clinical decision-making. The hemoglobin, albumin, lymphocyte, and platelet (HALP) score, an integrated immune-nutrition marker, has emerged as a potential prognostic tool in various malignancies. This meta-analysis evaluated the prognostic value of the HALP score in patients with digestive system cancers. A systematic search was performed in PubMed, PMC, and Web of Science database for studies assessing HALP scores calculated from pre-treatment blood tests and reporting survival outcomes in patients with digestive system cancers. Hazard ratios (HRs) with 95% confidence intervals (CIs) were pooled to evaluate the prognostic significance of the HALP score. A total of 30 articles comprising 34 studies and 9,389 patients were included. High HALP scores were significantly associated with improved survival outcomes. The pooled HR for overall survival (OS) was 1.762 (95% CI: 1.570–1.977, P < 0.001), and similar results were found for disease-free survival (DFS) (HR = 1.841, 95% CI: 1.311–2.585, P < 0.001), recurrence-free survival (RFS) (HR = 1.583, 95% CI: 1.374–1.824, P < 0.001), cancer-specific survival (CSS) (HR = 1.930, 95% CI: 1.590–2.341, P < 0.001), and progression-free survival (PFS) (HR = 1.444, 95% CI: 1.068–1.954, P = 0.017). Subgroup analyses confirmed the robustness of these findings across different treatment strategies and cancer types. Sensitivity and bias analyses (P = 0.103) supported the reliability of these results. The HALP score is a promising prognostic biomarker for digestive system cancers, offering potential for clinical application in personalizing treatment strategies. Future studies should aim to standardize methodologies and validate HALP in prospective multicenter trials.

20 November 2024 in World Journal of Surgical Oncology
Verified
Journal Article
Open access
PDF file
DYDongli Yu
Dongli Yu
JLJingting Liu
Jingting Liu
CMChunyan Meng
Chunyan Meng
BLBaoqing Liu
Baoqing Liu
JLJianhua Liao
Jianhua Liao
Digestive system cancers pose a significant global health challenge with high incidence and mortality rates. Inflammation is a key factor in cancer progression, necessitating reliable prognostic indicators. The pan-immune-inflammation value (PIV), as a new biomarker of immune-inflammatory response, has emerged as a potential prognostic biomarker for cancers. We performed a meta-analysis to evaluate the prognostic significance of PIV in digestive system cancers. Our search, up to June 2024, included 20 studies from 19 articles with 5037 patients. We extracted and analyzed data on PIV levels and assessed hazard ratios (HRs) for overall survival (OS), progression-free survival (PFS), disease-free survival (DFS), recurrence-free survival (RFS), and cancer-specific survival (CSS) using STATA 14.0. Our analysis found that high PIV levels were significantly associated with poor prognosis in patients with digestive system cancers. Specifically, high PIV was linked to shorter OS (HR = 2.039, P < 0.001), PFS (HR = 1.877, P = 0.028), DFS (HR = 1.624, P = 0.005), RFS (HR = 2.393, P = 0.037), and CSS (HR = 2.053, P < 0.001). Additionally, the adverse prognostic impact of high PIV on OS was consistent across different cancer types, including digestive tract, colorectal, esophageal, and hepatobiliary pancreatic cancers. Although some heterogeneity was observed, sensitivity and bias analyses confirmed the reliability of these findings. PIV was a valuable and practical prognostic marker for digestive system cancers, providing significant predictive value across multiple survival metrics. Its simplicity and minimal invasiveness nature support its potential integration into routine clinical practice.